FXR/TGR5 dual agonists such as INT-767 directly inhibit the TNFα-[NF-κB] axis, analogous to known techniques already employed to inhibit the expression of YY1.670 Besides upstream regulation, YY1 targeted therapy is likely to provide stronger and more relevant impacts for therapeutic modulation of NAFLD/NASH. Here, NFKB1 is linked to metabolic dysfunction-associated steatohepatitis.